Revolution Medicines, shared on LinkedIn:
“Today we reported our Q3 2026 financial results and corporate progress, including the milestone U.S. FDA approval and launch of our RAS(ON) multi-selective inhibitor for eligible adults with previously treated metastatic pancreatic cancer.
Key recent highlights include:
- Advanced U.S. commercialization and preparations for potential international approvals, including a positive opinion from the European Medicines Agency’s CHMP recommending marketing authorization in the European Union.
- Continued progress across our clinical development programs in pancreatic, lung and colorectal cancers, including advancing Phase 3 studies.
- Continued expansion of our global commercialization capabilities and support for patients and healthcare providers.
For more, including a link to the investor webcast”.
Read the full release.
Scientific contributions of Revolution Medicines
- Pioneering RAS(ON) inhibition: Focused on developing medicines that target active RAS proteins, addressing key drivers of cancer growth and progression in RAS-dependent tumors.
- Development of innovative oncology pipeline: Established a dedicated pipeline of investigational cancer therapies designed to target RAS-driven malignancies, with the goal of improving treatment options for patients with difficult-to-treat cancers.
- Advancement of Tri-Complex technology: Developed a proprietary Tri-Complex platform aimed at enabling selective targeting of RAS proteins through innovative molecular interactions.
- Focus on transforming cancer treatment: Built its research and development strategy around addressing significant unmet needs in oncology, particularly cancers driven by RAS mutations, through novel targeted therapeutic approaches.
You may also be interested in:
Lucy Flanders: Exploring KRAS-Targeted Interception for Pancreatic Cancer Prevention